ASLAN Forms Singapore Partnership to Develop mAb Fragment Drugs

ASLAN Pharma, a Singapore oncology biotech, will collaborate with Nanyang Technological University of Singapore to develop Modybodies, a novel type of stabilized heavy chain monoclonal antibody fragments. NTU will develop Modybodies for three targets specified by ASLAN, and ASLAN has an option to acquire global rights for the Modybodies under agreed-upon terms. ASLAN says Modybodies can penetrate tissues better than monoclonal antibodies because of their small size. More details.... Share this with colleagues: // //